Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) is a leading biotech company, headquartered in Boston, MA, that specializes in tackling serious conditions. They have brought to market several transformative treatments for cystic fibrosis (CF), sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT), and chronic/acute pain, and areI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend re ...

BREAKING: Stocks Rumble Higher As PayPal, UnitedHealth RallyArcutis Biotherapeutics (ARQT) smashed third-quarter expectations Tuesday and reported its first-ever positive net income, leading Arcutis stock to skyrocket.In late morning trades, Arcutis stock surged more than 24% to 24.49. Shares topped a profit-taking zone after, last month, breaking out of a cup base.The company makes Zoryve, a cream that treats skin conditions like psoriasis and eczema. During the third quarter, Zoryve generated $99.2 millio ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Points - Genprex, Inc. has announced a registered direct offering of 377,780 shares of common stock at a price of $9.00 per share, with potential additional gross proceeds of up to $6.6 million from short-term warrants [1][2] - The offering is expected to close around October 29, 2025, subject to customary closing conditions [1] - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2] Financial Details - The gross proceeds from the offering are anticipated to be approximately $3.4 million before deducting fees and expenses [2] - The short-term warrants will allow the purchase of up to 755,560 shares at an exercise price of $8.75 per share, which will be immediately exercisable [1][2] Regulatory Information - The shares are being offered under a "shelf" registration statement that was declared effective by the SEC on June 9, 2023 [3] - The unregistered warrants and underlying shares are being offered in a private placement and have not been registered under the Securities Act [4] Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes [6] - The company's lead product candidate, Reqorsa® Gene Therapy, is being evaluated in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [7] - Genprex's diabetes gene therapy approach aims to transform pancreatic alpha cells into functional beta-like cells to produce insulin [7]

Wall Street expects a year-over-year increase in earnings on higher revenues when Rhythm Pharmaceuticals, Inc. (RYTM) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 4, might help the stock move higher if these key numbers are ...

Shares of Tvardi Therapeutics (TVRD) have been struggling lately and have lost 21.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish cas ...

3rd Quarter 2025 Financial Results & Investor Day October 28, 2025 Legal Disclaimers This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Forward- looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financ ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of violations of federal securities laws related to misleading statements about its product SLK compared to BIMZELX [1][3]. Group 1: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives made false and misleading statements regarding the efficacy and clinical benefits of SLK compared to traditional monoclonal antibodies [3]. - Specific claims include that SLK and BIMZELX share the same molecular targets, and that SLK's unique structure does not provide superior clinical benefits or efficacy [3]. - Following the announcement of Phase 3 VELA program results, which showed SLK's failure to demonstrate competitive efficacy, MoonLake's stock price dropped by $55.75 per share, or 89.9%, closing at $6.24 [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased MoonLake securities between March 10, 2024, and September 29, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The deadline for seeking the role of lead plaintiff in the federal securities class action against MoonLake is December 15, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5].

Market Overview - The core stock market ETFs, particularly the Semiconductors Sector ETF (SMH) and the Biotechnology Sector ETF (IBB), show optimism similar to the S&P 500, Dow Industrials, and NASDAQ 100, with SMH reaching a new all-time high while IBB remains below its peak from 2021 [1] - The Russell 2000 ETF (IWM) is just below its all-time high established two weeks ago, indicating mixed price action that is more neutral than bullish [3] Sector Performance - The Retail Sector ETF (XRT) and Regional Banks ETF (KRE) are identified as the weakest links among core ETFs [2] - The Transportation Sector ETF (IYT) is barely above the 50-Day Moving Average and has been underperforming relative to the S&P 500 ETF (SPY), indicating a divergence in performance [3][4] - The IYT has been stuck in the middle of the monthly high and low, with two closes above the 50-DMA needed for a positive outlook [5] Economic Drivers - The underperformance of the U.S. Transportation Sector can be attributed to structural, cyclical, and investor-sentiment factors, including weak freight/demand growth and rising operational costs [4][8] - A shift in the economy towards services and digital goods is reducing the growth of heavy goods movement, impacting transportation sector performance [8] - Investor perception of a potential slowdown or mild recession is leading to early discounting of transportation stocks compared to other sectors [8]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [1][3]. Summary by Sections Company Overview - aTyr Pharma, Inc. is a biopharmaceutical company whose stock is traded on NASDAQ under the ticker ATYR [1]. Legal Investigation - The law firm Faruqi & Faruqi is encouraging investors who suffered losses from aTyr's securities between January 16, 2025, and September 12, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against aTyr, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [1]. Allegations - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [3]. - The EFZO-FIT study results indicated that efzofitimod did not significantly reduce the mean daily oral corticosteroid dose compared to placebo, with a reduction of only 2.79 mg for the drug versus 3.52 mg for placebo [4]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod compared to 40.2% on placebo [4]. Stock Performance - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [4].